Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mitomycin C + veliparib
- Development stage
- Phase 1
- Lead developer
- AbbVie
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
A combination therapy consisting of mitomycin C, a chemotherapy agent that produces double-strand DNA breaks, and veliparib, a PARP (poly(ADP-ribose) polymerase) inhibitor. This combination was studied in patients with solid tumors that have functional deficiency in homologous recombination repair, particularly those with defects in the Fanconi Anemia pathway. The combination works by mitomycin C creating DNA damage while veliparib blocks the enzymes needed for DNA repair, potentially leading to cancer cell death.
02
Targets
DNAPARP1 (Poly (adp-ribose) polymerase 1)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on mitomycin C + veliparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mitomycin C + veliparib.